Postmenopausal estrogen therapy and alzheimer disease

Overall negative findings

Rosebud O Roberts, Ruth H. Cha, David S Knopman, Ronald Carl Petersen, Walter A Rocca

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

An inverse association between estrogen therapy (ET) and Alzheimer disease (AD) has been reported in some, but not in all studies. We investigated the association between ET and AD in postmenopausal women using a population-based case-control design. Women who developed AD from 1985 through 1989 in Rochester, MN (cases, n=264) were individually matched by age (±1 y) to control women free of dementia from the same population (controls, n=264). ET exposure (≥6 mo after menopause) was ascertained by abstracting the complete medical records archived in the records-linkage system of the Rochester Epidemiology Project. The frequency of ET use was similar in cases (11.4%) and controls [10.6%; odds ratio=1.10; 95% confidence interval (CI)=0.63-1.93]. However, cases who used ET had a suggestive trend for an earlier age at start of ET compared with controls (median, 49.0 vs. 50.5 y; P=0.06). Although smoking (ever vs. never) was not associated with AD overall, we observed an interaction between smoking and ET. The odds ratio of AD in ET users was 4.55 (95% CI=1.33-15.53) among smokers, but was 0.68 (95% CI=0.35-1.32) among never-smokers (P for interaction=0.01). Our findings do not confirm a significant association between ET and AD overall; however, the possible interaction with smoking deserves further study.

Original languageEnglish (US)
Pages (from-to)141-146
Number of pages6
JournalAlzheimer Disease and Associated Disorders
Volume20
Issue number3
DOIs
StatePublished - Jul 2006

Fingerprint

Alzheimer Disease
Estrogens
Therapeutics
Smoking
Confidence Intervals
Odds Ratio
Implosive Therapy
Population Control
Menopause
Medical Records
Dementia
Epidemiology
Population

Keywords

  • Alzheimer disease
  • Case-control study
  • Dementia
  • Epidemiology
  • Postmenopausal estrogen therapy
  • Smoking

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Postmenopausal estrogen therapy and alzheimer disease : Overall negative findings. / Roberts, Rosebud O; Cha, Ruth H.; Knopman, David S; Petersen, Ronald Carl; Rocca, Walter A.

In: Alzheimer Disease and Associated Disorders, Vol. 20, No. 3, 07.2006, p. 141-146.

Research output: Contribution to journalArticle

@article{d675821b10d7437b8a71451b936ea754,
title = "Postmenopausal estrogen therapy and alzheimer disease: Overall negative findings",
abstract = "An inverse association between estrogen therapy (ET) and Alzheimer disease (AD) has been reported in some, but not in all studies. We investigated the association between ET and AD in postmenopausal women using a population-based case-control design. Women who developed AD from 1985 through 1989 in Rochester, MN (cases, n=264) were individually matched by age (±1 y) to control women free of dementia from the same population (controls, n=264). ET exposure (≥6 mo after menopause) was ascertained by abstracting the complete medical records archived in the records-linkage system of the Rochester Epidemiology Project. The frequency of ET use was similar in cases (11.4{\%}) and controls [10.6{\%}; odds ratio=1.10; 95{\%} confidence interval (CI)=0.63-1.93]. However, cases who used ET had a suggestive trend for an earlier age at start of ET compared with controls (median, 49.0 vs. 50.5 y; P=0.06). Although smoking (ever vs. never) was not associated with AD overall, we observed an interaction between smoking and ET. The odds ratio of AD in ET users was 4.55 (95{\%} CI=1.33-15.53) among smokers, but was 0.68 (95{\%} CI=0.35-1.32) among never-smokers (P for interaction=0.01). Our findings do not confirm a significant association between ET and AD overall; however, the possible interaction with smoking deserves further study.",
keywords = "Alzheimer disease, Case-control study, Dementia, Epidemiology, Postmenopausal estrogen therapy, Smoking",
author = "Roberts, {Rosebud O} and Cha, {Ruth H.} and Knopman, {David S} and Petersen, {Ronald Carl} and Rocca, {Walter A}",
year = "2006",
month = "7",
doi = "10.1097/00002093-200607000-00004",
language = "English (US)",
volume = "20",
pages = "141--146",
journal = "Alzheimer Disease and Associated Disorders",
issn = "0893-0341",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Postmenopausal estrogen therapy and alzheimer disease

T2 - Overall negative findings

AU - Roberts, Rosebud O

AU - Cha, Ruth H.

AU - Knopman, David S

AU - Petersen, Ronald Carl

AU - Rocca, Walter A

PY - 2006/7

Y1 - 2006/7

N2 - An inverse association between estrogen therapy (ET) and Alzheimer disease (AD) has been reported in some, but not in all studies. We investigated the association between ET and AD in postmenopausal women using a population-based case-control design. Women who developed AD from 1985 through 1989 in Rochester, MN (cases, n=264) were individually matched by age (±1 y) to control women free of dementia from the same population (controls, n=264). ET exposure (≥6 mo after menopause) was ascertained by abstracting the complete medical records archived in the records-linkage system of the Rochester Epidemiology Project. The frequency of ET use was similar in cases (11.4%) and controls [10.6%; odds ratio=1.10; 95% confidence interval (CI)=0.63-1.93]. However, cases who used ET had a suggestive trend for an earlier age at start of ET compared with controls (median, 49.0 vs. 50.5 y; P=0.06). Although smoking (ever vs. never) was not associated with AD overall, we observed an interaction between smoking and ET. The odds ratio of AD in ET users was 4.55 (95% CI=1.33-15.53) among smokers, but was 0.68 (95% CI=0.35-1.32) among never-smokers (P for interaction=0.01). Our findings do not confirm a significant association between ET and AD overall; however, the possible interaction with smoking deserves further study.

AB - An inverse association between estrogen therapy (ET) and Alzheimer disease (AD) has been reported in some, but not in all studies. We investigated the association between ET and AD in postmenopausal women using a population-based case-control design. Women who developed AD from 1985 through 1989 in Rochester, MN (cases, n=264) were individually matched by age (±1 y) to control women free of dementia from the same population (controls, n=264). ET exposure (≥6 mo after menopause) was ascertained by abstracting the complete medical records archived in the records-linkage system of the Rochester Epidemiology Project. The frequency of ET use was similar in cases (11.4%) and controls [10.6%; odds ratio=1.10; 95% confidence interval (CI)=0.63-1.93]. However, cases who used ET had a suggestive trend for an earlier age at start of ET compared with controls (median, 49.0 vs. 50.5 y; P=0.06). Although smoking (ever vs. never) was not associated with AD overall, we observed an interaction between smoking and ET. The odds ratio of AD in ET users was 4.55 (95% CI=1.33-15.53) among smokers, but was 0.68 (95% CI=0.35-1.32) among never-smokers (P for interaction=0.01). Our findings do not confirm a significant association between ET and AD overall; however, the possible interaction with smoking deserves further study.

KW - Alzheimer disease

KW - Case-control study

KW - Dementia

KW - Epidemiology

KW - Postmenopausal estrogen therapy

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=33747454964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747454964&partnerID=8YFLogxK

U2 - 10.1097/00002093-200607000-00004

DO - 10.1097/00002093-200607000-00004

M3 - Article

VL - 20

SP - 141

EP - 146

JO - Alzheimer Disease and Associated Disorders

JF - Alzheimer Disease and Associated Disorders

SN - 0893-0341

IS - 3

ER -